Galena Biopharma Pipeline Developments Third Quarter 2016 Results and Outlook

Galena Biopharma (NASDAQ:GALE), the biotechnology company focused on treating blood diseases and cancer, are looked at by Traders News Source, an equity research firm specializing in small and micro-cap securities, to see whether they can recover further lost ground after a rough 2016. They announced earnings for the third quarter of 2016 on November 9, 2016 and shares spiked recently on a positive regulatory development.
 
As quoted in the press release:

Its most advanced drug is GALE-401. GALE-401 has the potential for treating the rare blood disease essential thrombocythemia (“ET”). Regarding its blood disease drug GALE-401, the addressable market is small, but there also appears to be no visible competition. Roughly 150,000 people are diagnosed with thrombocytosis, most of whom are treated.

Click here for the full text release.